The licensed technology, with pending patent applications, has been developed by Vincent Falanga, chairman of the department of dermatology and skin surgery at Roger Williams Medical Center, Providence,
Anti-platelet derived growth factor (anti-PDGF) therapy resulted in enhanced visual outcome and was associated with significant neovascular regression. Approximately 59% of patients treated with anti-PDGF and anti-vascular endothelial
At March 31, 2009, DURECT had cash and investments of $47.0 million, compared to cash and investments of $52.7 million at December 31, 2008; these figures include restricted
Total disposable revenues were $2.8 million versus $3.0 million in the third quarter of fiscal 2008. Disposable revenues associated with the company’s core AXP AutoXpress Platform (AXP) and
The company’s case volume in the first quarter increased to 31,765 cases, up 32%, compared with the same period in 2008. The customer base of oncology and pathology
EXACT’s total revenues increased due to strategic relationship with Genzyme Corp. Exact in January entered into an intellectual property transaction with Genzyme that generated $17.2 million in cash.
Excelsior Medical, a medical device company, has received 510k clearance to sell its SwabCap luer access valve disinfection cap. According to Excelsior Medical, SwabCap is designed to assist
Juan Han, chairman and CEO of China Aoxing, said: “We are very excited to have another drug approval in year 2009. This approval further underscores China Aoxing’s long-term
Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca. AstraZeneca will own
Izasa will target early adopters who recognize the benefits of utilizing the unique fluid balancing capabilities of RenalGuard in a cath lab setting during cardiovascular imaging procedures for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.